70 Years of EUDRAGIT®

We go beyond to formulate health with science

Making five generations healthier with EUDRAGIT® polymers

EUDRAGIT® is the industry’s preferred portfolio of functional polymers for use with oral drug products. The breadth, versatility and history of EUDRAGIT®, combined with Evonik’s range of drug delivery technologies, formulation and cGMP manufacturing services, provides pharmaceutical companies with unrivalled safety and functional reliability for their oral solid dosage forms.

Our product may have been at your side for five generations,

but we are constantly inspired by innovation.

Click to download
Click to download

Seven decades ago, scientists in Darmstadt, Germany, made a significant discovery that was to have a profound impact on the pharmaceutical industry. They found that polymers derived from esters of acrylic and methacrylic acid could create highly effective coatings for tablets. EUDRAGIT®, introduced 70 years ago, expanded the possibilities for drug developers and manufacturers with innovative functionalities, such as gastro-resistance, moisture protection, and taste and odor masking.

EUDRAGIT® - What’s in a name?

The name EUDRAGIT® is built from a combination of three syllables: the Ancient Greek syllable “eu” (pronounced “oi”) meaning “good”, with “dra“ from the French word “dragée” which means coating, and finally “git” for "gastrointestinal tract". When the name was created, it made sense, described the product, and had a nice, sophisticated ring. For German speakers “oi-drah-git” sounds really good. Only later on, did the creators of EURDAGIT® realize that in many other languages the name was less intuitive. Especially English speaking customers and business partners wondered why a product would be called “You-drag-it”! But the name stuck and has been a successful brand for 70 years.

Over the past decades, innovation has never ceased. In 1968, quaternary amino groups were incorporated to produce film coatings that would remain insoluble across the entire pH spectrum, providing pH-independent time-controlled sustained release effects. To increase product purity and address customer handling and processing issues, substance polymerization was implementended and solid forms were made available as granules and powders. Later on, emulsion polymerization was developed to create aqueous dispersons and enable coating technologies without solvents.

Today, the development of EUDRAGIT® polymers continues. With a growing and aging population in many parts of the world, Evonik will build on its innovations in the past few years such as EUDRACAP® functional capsules, and innovate these polymers into next-generation solutions.

23,000 patents

More than 23,000 patents mention the keyword EUDRAGIT®

80 countries

Today, customers in over 80 countries use EUDRAGIT® polymers in their formulations. 

10,000 publications

More than 10,000 scientific publications contain the term EUDRAGIT®

Our future tasks may be challenging,

but we are always in the right place at the right time.

Click to download
Click to download

Drug release profiles refer to the rate and pattern at which a drug is released from its delivery system over time. The development of drug release profiles can be traced back to the 1940s, when researchers began studying the dissolution of drugs in the body and the factors that affect drug release. In the 1950s and 1960s, researchers began developing sustained release formulations, which could release drugs over an extended period of time. This was achieved by incorporating the drugs into a matrix or coating that could control the rate of drug release. Over the past 70 years, EUDRAGIT® polymers have played an important role in addressing some of the challenges faced by drug developers in different types of release systems.

One of the main advantages of EUDRAGIT® polymers is their ability to control drug release by modulating the pH of the release environment. This is particularly useful for delayed release formulations, where the drug needs to be protected from the acidic environment of the stomach before it can be absorbed in the intestine. EUDRAGIT® polymers can be formulated to dissolve at specific pH values, allowing for the drug to be released in a controlled manner.

To achieve sustained release formulations, the molecular weight and composition of EUDRAGIT® polymers can be altered to control the rate of drug release. This is particularly useful for drugs that need to be taken less frequently, as sustained release formulations can maintain therapeutic levels of the drug in the body for longer periods of time.

Today, EUDRAGIT® polymers can be used to match almost any release profile. Either alone or in combination they can create oral solid drugs with immediate, delayed, sustained, pulsatile, accelerated, or zero order release profiles. Drug release profiles continue to be an active area of research, with a focus on developing more precise and targeted drug delivery systems.

Want to learn more?

Visit our website to learn more about EUDRAGIT® polymers and their various application areas.

Want to hear it from our experts directly? Then our EUDRAGIT® Masterclass Series might be something for you.

In six comprehensive video courses our formulation experts lead you through all relevant aspects from polymer properties and formulation basics to advanced oral drug delivery solutions and troubleshooting.

All you need to access the series is a free account for our online platform onCare. Just click on the videos to create your account or login to onCare.


Celebrate with us